Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Charles Reinhart - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Christian Pedetti - Senior Manager, Investor Relations Conference Call Participants Gregory Renza - RBC Capital Markets David Amsellem - Piper Sandler Gary Nachman - Raymond James Balaji Prasad - Barclays Operator Thank you for standing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorpora ...

FOR IMMEDIATE RELEASE See "Non-GAAP Financial Information" below. "Sales are off to a solid start for all three of our trusted, opioid-sparing products and we remain sharply focused on driving accelerated growth in 2025 and beyond," said Frank D. Lee, chief executive officer of Pacira BioSciences. "We are pleased with the progress we are making advancing the launch of EXPAREL in two new lower extremity nerve block indications, and we are receiving positive market receptivity across all sites of care. We are ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Conference Call February 29, 2024 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Anthony Malloy - Chief Legal Counsel Charles Reinhart - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Conference Call Participants David Amsellem - Piper Sandler Gregory Renza - RBC Capital Markets Gary Nachman - Raymond James Leszek Sulewski - Truist Securities Balaji Prasad - Barclays Serge B ...

Revenue Performance - EXPAREL net product sales remained flat at $538.12 million in 2023 compared to $536.90 million in 2022, with a 4% increase in gross vial volume offset by a 3% decrease in net selling price per unit [446]. - ZILRETTA revenue increased by 5% to $111.10 million in 2023, driven by a 3% increase in kit volume and a 2% increase in selling price per unit [447]. - iovera° net product sales rose by 29% to $19.69 million in 2023, primarily due to a 33% increase in Smart Tip volume [447]. - Total revenues for 2023 were $674.98 million, a 1% increase from $666.82 million in 2022 [446]. Gross Margin and Expenses - Gross margin improved to 73% in 2023, up from 70% in 2022, mainly due to lower inventory reserves and reduced royalty expenses [449]. - Total research and development expenses decreased by 10% to $76.26 million in 2023, representing 11% of total revenue [453]. - Clinical and preclinical development expenses fell by 46% to $24.47 million in 2023, attributed to the completion of certain trials [454]. - Product development and manufacturing capacity expansion expenses increased by 35% to $33.37 million, driven by new product development costs and scale-up activities for EXPAREL [455]. - Total selling, general and administrative expenses rose by 6% in 2023, amounting to $269.4 million, which is 40% of total revenue [458]. - Sales and marketing expenses increased by 6% in 2023 to $153.0 million, driven by marketing investments and educational initiatives [459]. - General and administrative expenses increased by 12% in 2023 to $82.7 million, primarily due to legal fees from ongoing litigation [461]. Cash Flow and Financing - Net cash provided by operating activities was $154.6 million in 2023, an increase of $9.4 million from 2022 [479]. - Net cash provided by investing activities was $77.5 million in 2023, reflecting $99.5 million from available-for-sale investment maturities [480]. - Net cash used in financing activities was $183.0 million in 2023, including a $296.9 million repayment of TLB Term Loan principal [482]. - The company had an accumulated deficit of $106.8 million and cash and cash equivalents of $281.0 million as of December 31, 2023 [476]. Debt and Interest - Interest expense decreased by 49% in 2023 to $20.3 million, attributed to the TLA Term Loan entered in March 2023 [470]. - As of December 31, 2023, the outstanding principal on the TLA Term Loan was $116.6 million, with a borrowing rate of 8.46% [485]. - The company made a scheduled principal payment of $2.8 million and $30.6 million in voluntary principal prepayments during the year ended December 31, 2023, resulting in no required principal payments for 2024 [485]. - The company incurred a $16.9 million loss on early extinguishment of debt after repaying the $287.5 million principal on the TLB Term Loan [488]. - The TLA Term Loan has a principal amount of $150.0 million, with an outstanding principal of $116.6 million as of December 31, 2023, and an interest rate of 8.46% [508]. Tax and Equity - The effective tax rate for 2023 was 32%, significantly higher than the U.S. statutory tax rate of 21% due to non-deductible expenses [474]. - The company has raised $344.5 million in net proceeds from the sale of common stock and other equity securities since its inception in December 2006 [484]. Regulatory and Management Changes - The FDA approved the sNDA for a 200-liter EXPAREL manufacturing suite in February 2024, expected to enhance gross margins over time [445]. - The company appointed Frank D. Lee as CEO in December 2023, bringing over three decades of experience in the biotech and pharmaceutical industry [444]. - Regulatory and other research and development expenses increased by 22% in 2023 compared to 2022 due to increased enrollment and additional sites for an observational registry study [456]. Commitments and Risks - The company has potential milestone payments of up to $372.3 million related to the Flexion Acquisition, contingent on achieving certain regulatory and commercial milestones [494]. - As of December 31, 2023, the outstanding principal on the 2025 Convertible Senior Notes was $402.5 million, maturing on August 1, 2025 [489]. - The company had net minimum commitments of $78.6 million for operating leases as of December 31, 2023, with $13.0 million due in 2024 [496]. - The company is required to maintain a Senior Secured Net Leverage Ratio of no greater than 3.00 to 1.00 and a Fixed Charge Coverage Ratio of no less than 1.50 to 1.00 under the TLA Credit Agreement [486]. - Accounts receivable are primarily concentrated with three large wholesalers, posing a risk of material adverse impact on financial condition if there is non-performance or non-payment [510].

PCRX Pacira BioSciences Corporate Presentation November 2023 Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Secu ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of Investor Relations Dave Stack - Chairman & Chief Executive Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to the Q3 2023 Pacira BioSciences Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' pres ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other Jurisd ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - Chairman & CEO Charles Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Gregory Renza - RBC Capital Markets Glen Santangelo - Jefferies Rohit Bhasin - Needham & Company Boris Peaker - TD Cowen Operator Good day and thank you for standing by. Welcome to the Q2, 2023 Pacira BioSciences Inc. Earnings Conference Call. At this t ...